

Kent and Medway SACT Protocol

CarboMV for Urothelial Cancer

Indication	Palliative treatment for urothelial cancer
Treatment Intent	Palliative
Funding approval required	No
Drugs / Doses / Administration	<p>Day 1: VINBLASTINE (4mg/m²) IV in 50ml 0.9% sodium chloride over 5-10 minutes METHOTREXATE (30mg/m²) as a slow IV bolus through the side of a fast running 0.9% sodium chloride intravenous infusion CARBOPLATIN (AUC 5) Dose = AUC x (GFR + 25) IV in 500ml 5% glucose over 30 minutes</p> <p>Day 8: VINBLASTINE (4mg/m²) IV in 50ml 0.9% sodium chloride over 5-10 minutes METHOTREXATE (30mg/m²) as a slow IV bolus through the side of a fast running 0.9% sodium chloride intravenous infusion</p> <p>NB Cap BSA at 2m²</p>
Frequency and number of cycles	Every 21 days for 6 cycles.
Emetogenic potential (follow K&M guidelines for the management of SACT induced nausea and vomiting)	<p>Day 1: High Pre Chemo: Dexamethasone 8mg po and Ondansetron iv 16mg (if <75yrs) / 8mg (if ≥75yrs) TTO: Dexamethasone 6mg po om for 3 days and metoclopramide 10mg po up to 3 times a day for 3 days, then 10mg up to 3 times a day as required (do not take for more than 5 days continuously).</p> <p>Day 8: Minimal Pre Chemo: Metoclopramide 20mg po TTO: Metoclopramide 10mg po up to 3 times a day for 3 days, then 10mg up to 3 times a day as required (max. 30mg per day including 20mg pre-chemo dose). Do not take for more than 5 days continuously.</p>
Pre-medication (if required) Drugs / doses / administration	Anti-emetics only (see above)
Hydration (if required, follow K&M cisplatin hydration guidelines if appropriate)	N/A
Monitoring parameters pre-treatment	<ul style="list-style-type: none"> • EDTA or C&G may be used to measure GFR prior to cycle 1. Must be ≥30ml/min • Discuss with consultant if Creatinine clearance drops by >= 25% • Monitor FBC (day 1 & 8), U&Es and LFTs (day 1) at each cycle • Dose reduction should be considered if grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&V and alopecia). Delay until resolution of toxicity to ≤ grade 1 • Omit methotrexate in the event of third space (pleural effusion / ascites) • Day 1 If neuts ≥ 1.5 and PLT ≥100 continue with treatment. If neuts 1.0-1.4 and Plts ≥100 d/w consultant. If neuts <1.0 or PLT <100 defer treatment and consider dose reduction • Day 8 If neuts <1.0 or PLT <100 omit treatment.
Post treatment observation (if required)	N/A
Additional TTOs	Calcium folinate 15mg po every 6 hours for 6 doses, starting 24 hours after methotrexate on days 1 and 8 (dispense 12 doses)
Reference(s)	K&M SACT proforma URO-008 CMV May 15 v4
Comments	BSA to be capped at 2.0m ²

Disclaimer: This document is for use only within Kent and Medway. No responsibility will be accepted for the accuracy of this information when used elsewhere.

Kent and Medway SACT Protocol

Document Control

Protocol No:	URO-027	New protocol (carboplatin as a replacement for cisplatin)
Version:	1 Final	
Supersedes version:		
Date:	13/7/2017	
Authorising consultant (usually NOG Chair)	C Thomas	
Written by:	C Waters	
Checked by:	K Miller	